---
document_datetime: 2026-01-19 10:15:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/aprovel.html
document_name: aprovel.html
version: success
processing_time: 0.1930198
conversion_datetime: 2026-01-20 20:17:09.836022
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Academia](/en/partners-networks/academia)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Aprovel

# Aprovel

[RSS](/en/individual-human-medicine.xml/66899)

##### Authorised

This medicine is authorised for use in the European Union

irbesartan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Aprovel](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-82832)
- [More information on Aprovel](#more-information-on-aprovel-816)
- [More information on Aprovel](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Aprovel. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aprovel.

Expand section

Collapse section

## What is Aprovel?

Aprovel is a medicine that contains the active substance irbesartan. It is available as tablets (75, 150 and 300 mg).

## What is Aprovel used for?

Aprovel is used in adults who have essential hypertension (high blood pressure). 'Essential' means that the hypertension has no obvious cause. Aprovel is also used to treat kidney disease in adults with hypertension and type-2 diabetes. The medicine can only be obtained with a prescription.

## How is Aprovel used?

The usual recommended dose of Aprovel is 150 mg once a day. If the blood pressure is not sufficiently controlled, the dose can be increased to 300 mg a day or other medicines for hypertension can be added, such as hydrochlorothiazide. A starting dose of 75 mg can be used in patients receiving haemodialysis (a blood clearance technique) or in patients over 75 years of age.

In patients with hypertension and type-2 diabetes, Aprovel is added to some other treatments for hypertension. Treatment is started at 150 mg once a day and is usually increased to 300 mg once a day.

## How does Aprovel work?

The active substance in Aprovel, irbesartan, is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, irbesartan stops the hormone having an effect, allowing the blood vessels to widen. This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a stroke.

## How has Aprovel been studied?

Aprovel was originally studied in 11 trials for its effects on blood pressure. Aprovel was compared with placebo (a dummy treatment) in 712 patients and with other medicines for hypertension (atenolol, enalapril or amlodipine) in 823 patients. Its use in combination with hydrochlorothiazide was also examined in 1,736 patients. The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).

For the treatment of kidney disease, Aprovel was studied in two large studies involving a total of 2,326 patients with type-2 diabetes. Aprovel was used for two years or more. One study looked at markers of kidney damage by measuring whether the kidneys were releasing the protein albumin into the urine. The second study looked at whether Aprovel increased the time taken until the patients' blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died. In this study, Aprovel was compared with placebo and with amlodipine.

## What benefit has Aprovel shown during the studies?

In the blood pressure studies, Aprovel was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension. When used with hydrochlorothiazide, the effects of the two medicines were additive.

In the first kidney-disease study, Aprovel was more effective than placebo at reducing the risk of developing kidney damage as measured by protein excretion. In the second kidney-disease study, Aprovel reduced the relative risk of a doubling of blood creatinine levels, needing a kidney transplant or dialysis, or death during the study by 20% in comparison with placebo. There was a 23% relative risk reduction compared with amlodipine. The main benefit was on the effect on blood creatinine levels.

## What is the risk associated with Aprovel?

The most common side effect with Aprovel (seen in more than 1 patient in 10) is hyperkalaemia (high blood potassium levels). For the full list of all side effects reported with Aprovel, see the package leaflet.

Aprovel must not be used in people who are hypersensitive (allergic) to irbesartan or any of the other ingredients. It must not be used in women who are more than three months pregnant. Its use during the first three months of pregnancy is not recommended. Aprovel in combination with aliskiren-containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.

## Why has Aprovel been approved?

The CHMP decided that Aprovel's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Aprovel

The European Commission granted a marketing authorisation valid throughout the European Union for Aprovel on 27 August 1997.

For more information about treatment with Aprovel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Aprovel : EPAR - Summary for the public

English (EN) (74.21 KB - PDF)

**First published:** 05/05/2009

**Last updated:** 23/09/2013

[View](/en/documents/overview/aprovel-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-487)

български (BG) (101.22 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/bg/documents/overview/aprovel-epar-summary-public_bg.pdf)

español (ES) (74.79 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/es/documents/overview/aprovel-epar-summary-public_es.pdf)

čeština (CS) (99.96 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/cs/documents/overview/aprovel-epar-summary-public_cs.pdf)

dansk (DA) (74.52 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/da/documents/overview/aprovel-epar-summary-public_da.pdf)

Deutsch (DE) (75.67 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/de/documents/overview/aprovel-epar-summary-public_de.pdf)

eesti keel (ET) (74.07 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/et/documents/overview/aprovel-epar-summary-public_et.pdf)

ελληνικά (EL) (101.51 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/el/documents/overview/aprovel-epar-summary-public_el.pdf)

français (FR) (75.89 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/fr/documents/overview/aprovel-epar-summary-public_fr.pdf)

hrvatski (HR) (92.32 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/hr/documents/overview/aprovel-epar-summary-public_hr.pdf)

italiano (IT) (74.46 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/it/documents/overview/aprovel-epar-summary-public_it.pdf)

latviešu valoda (LV) (97.06 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/lv/documents/overview/aprovel-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (96.41 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/lt/documents/overview/aprovel-epar-summary-public_lt.pdf)

magyar (HU) (94.55 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/hu/documents/overview/aprovel-epar-summary-public_hu.pdf)

Malti (MT) (100.47 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/mt/documents/overview/aprovel-epar-summary-public_mt.pdf)

Nederlands (NL) (74.38 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/nl/documents/overview/aprovel-epar-summary-public_nl.pdf)

polski (PL) (100.37 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/pl/documents/overview/aprovel-epar-summary-public_pl.pdf)

português (PT) (74.83 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/pt/documents/overview/aprovel-epar-summary-public_pt.pdf)

română (RO) (97.24 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/ro/documents/overview/aprovel-epar-summary-public_ro.pdf)

slovenčina (SK) (98.84 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/sk/documents/overview/aprovel-epar-summary-public_sk.pdf)

slovenščina (SL) (91.72 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/sl/documents/overview/aprovel-epar-summary-public_sl.pdf)

Suomi (FI) (73.91 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/fi/documents/overview/aprovel-epar-summary-public_fi.pdf)

svenska (SV) (74.67 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

23/09/2013

[View](/sv/documents/overview/aprovel-epar-summary-public_sv.pdf)

## Product information

Aprovel : EPAR - Product Information

English (EN) (939.38 KB - PDF)

**First published:** 22/04/2009

**Last updated:** 19/01/2026

[View](/en/documents/product-information/aprovel-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-884)

български (BG) (1.49 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/bg/documents/product-information/aprovel-epar-product-information_bg.pdf)

español (ES) (488.72 KB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/es/documents/product-information/aprovel-epar-product-information_es.pdf)

čeština (CS) (1.16 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/cs/documents/product-information/aprovel-epar-product-information_cs.pdf)

dansk (DA) (928 KB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/da/documents/product-information/aprovel-epar-product-information_da.pdf)

Deutsch (DE) (1.11 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/de/documents/product-information/aprovel-epar-product-information_de.pdf)

eesti keel (ET) (1015.55 KB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/et/documents/product-information/aprovel-epar-product-information_et.pdf)

ελληνικά (EL) (1.43 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/el/documents/product-information/aprovel-epar-product-information_el.pdf)

français (FR) (1.14 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/fr/documents/product-information/aprovel-epar-product-information_fr.pdf)

hrvatski (HR) (1 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/hr/documents/product-information/aprovel-epar-product-information_hr.pdf)

íslenska (IS) (1.31 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/is/documents/product-information/aprovel-epar-product-information_is.pdf)

italiano (IT) (942.79 KB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/it/documents/product-information/aprovel-epar-product-information_it.pdf)

latviešu valoda (LV) (1.26 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/lv/documents/product-information/aprovel-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.16 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/lt/documents/product-information/aprovel-epar-product-information_lt.pdf)

magyar (HU) (1.57 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/hu/documents/product-information/aprovel-epar-product-information_hu.pdf)

Malti (MT) (1.41 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/mt/documents/product-information/aprovel-epar-product-information_mt.pdf)

Nederlands (NL) (1.08 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/nl/documents/product-information/aprovel-epar-product-information_nl.pdf)

norsk (NO) (1.82 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/no/documents/product-information/aprovel-epar-product-information_no.pdf)

polski (PL) (1.32 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/pl/documents/product-information/aprovel-epar-product-information_pl.pdf)

português (PT) (966.04 KB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/pt/documents/product-information/aprovel-epar-product-information_pt.pdf)

română (RO) (1.21 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/ro/documents/product-information/aprovel-epar-product-information_ro.pdf)

slovenčina (SK) (1.13 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/sk/documents/product-information/aprovel-epar-product-information_sk.pdf)

slovenščina (SL) (1.19 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/sl/documents/product-information/aprovel-epar-product-information_sl.pdf)

Suomi (FI) (1015.23 KB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/fi/documents/product-information/aprovel-epar-product-information_fi.pdf)

svenska (SV) (1.03 MB - PDF)

**First published:**

22/04/2009

**Last updated:**

19/01/2026

[View](/sv/documents/product-information/aprovel-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000310720 15/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Aprovel : EPAR - All Authorised presentations

English (EN) (19.97 KB - PDF)

**First published:** 17/04/2007

**Last updated:** 17/04/2007

[View](/en/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_en.pdf)

[Other languages (20)](#file-language-dropdown-1000)

български (BG) (106.66 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/bg/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_bg.pdf)

español (ES) (23.05 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/es/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_es.pdf)

čeština (CS) (19.41 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/cs/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (22.05 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/da/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (22.47 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/de/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (23.55 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/et/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (107.06 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/el/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_el.pdf)

français (FR) (23.32 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/fr/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (22.66 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/it/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (22.68 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/lv/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (107.41 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/lt/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (61.39 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/hu/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (22.32 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/nl/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_nl.pdf)

polski (PL) (62.85 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/pl/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.29 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/pt/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_pt.pdf)

română (RO) (103.07 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/ro/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (23.3 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/sk/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (60 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/sl/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (22.88 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/fi/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23 KB - PDF)

**First published:**

17/04/2007

**Last updated:**

17/04/2007

[View](/sv/documents/all-authorised-presentations/aprovel-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Aprovel Active substance irbesartan International non-proprietary name (INN) or common name irbesartan Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09CA04

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension.

Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen.

## Authorisation details

EMA product number EMEA/H/C/000141 Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail

Marketing authorisation issued 26/08/1997 Revision 51

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Aprovel : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.65 KB - PDF)

**First published:** 11/02/2025

**Last updated:** 19/01/2026

[View](/en/documents/procedural-steps-after/aprovel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Aprovel : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (282.68 KB - PDF)

**First published:** 05/05/2009

**Last updated:** 11/02/2025

[View](/en/documents/procedural-steps-after/aprovel-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Aprovel : EPAR - Scientific conclusions - Annex IV

English (EN) (99.42 KB - PDF)

**First published:** 22/05/2019

[View](/en/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_en.pdf)

[Other languages (22)](#file-language-dropdown-494)

български (BG) (136.15 KB - PDF)

**First published:**

22/05/2019

[View](/bg/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_bg.pdf)

español (ES) (98.31 KB - PDF)

**First published:**

22/05/2019

[View](/es/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_es.pdf)

čeština (CS) (131.08 KB - PDF)

**First published:**

22/05/2019

[View](/cs/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_cs.pdf)

dansk (DA) (96.12 KB - PDF)

**First published:**

22/05/2019

[View](/da/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_da.pdf)

Deutsch (DE) (100.2 KB - PDF)

**First published:**

22/05/2019

[View](/de/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_de.pdf)

eesti keel (ET) (94.4 KB - PDF)

**First published:**

22/05/2019

[View](/et/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_et.pdf)

ελληνικά (EL) (142.79 KB - PDF)

**First published:**

22/05/2019

[View](/el/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_el.pdf)

français (FR) (97.56 KB - PDF)

**First published:**

22/05/2019

[View](/fr/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_fr.pdf)

hrvatski (HR) (125.02 KB - PDF)

**First published:**

22/05/2019

[View](/hr/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

22/05/2019

[View](/it/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_it.pdf)

latviešu valoda (LV) (130.68 KB - PDF)

**First published:**

22/05/2019

[View](/lv/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_lv.pdf)

lietuvių kalba (LT) (130.84 KB - PDF)

**First published:**

22/05/2019

[View](/lt/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_lt.pdf)

magyar (HU) (119.82 KB - PDF)

**First published:**

22/05/2019

[View](/hu/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_hu.pdf)

Malti (MT) (133.78 KB - PDF)

**First published:**

22/05/2019

[View](/mt/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_mt.pdf)

Nederlands (NL) (99.3 KB - PDF)

**First published:**

22/05/2019

[View](/nl/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

22/05/2019

[View](/pl/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

22/05/2019

[View](/pt/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_pt.pdf)

română (RO) (128.25 KB - PDF)

**First published:**

22/05/2019

[View](/ro/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_ro.pdf)

slovenčina (SK) (119.14 KB - PDF)

**First published:**

22/05/2019

[View](/sk/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_sk.pdf)

slovenščina (SL) (124.14 KB - PDF)

**First published:**

22/05/2019

[View](/sl/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_sl.pdf)

Suomi (FI) (97.12 KB - PDF)

**First published:**

22/05/2019

[View](/fi/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_fi.pdf)

svenska (SV) (96.85 KB - PDF)

**First published:**

22/05/2019

[View](/sv/documents/scientific-conclusion/aprovel-epar-scientific-conclusions-annex-iv_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report

Adopted

Reference Number: EMA/217823/2019

English (EN) (531.32 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf)

Aprovel-H-C-PSUSA-00001782/201508 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/367566/2016

English (EN) (68.1 KB - PDF)

**First published:** 15/07/2016

**Last updated:** 15/07/2016

[View](/en/documents/scientific-conclusion/aprovel-h-c-psusa-00001782201508-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Aprovel-H-C-141-A31-0154 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommenda...

English (EN) (48.81 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_en.pdf)

[Other languages (22)](#file-language-dropdown-333)

български (BG) (87.49 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/bg/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/es/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/cs/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/da/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/de/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/et/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/el/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fr/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hr/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/it/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lv/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lt/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hu/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/mt/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/nl/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pl/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pt/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/ro/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sk/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sl/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fi/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sv/documents/scientific-conclusion/aprovel-h-c-141-a31-0154-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_sv.pdf)

Aprovel-H-C-141-A31-0154 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/variation-report/aprovel-h-c-141-a31-0154-epar-assessment-report-article-31_en.pdf)

Aprovel-H-C-141-II-0148 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/220046/2013

English (EN) (238.14 KB - PDF)

**First published:** 23/09/2013

**Last updated:** 23/09/2013

[View](/en/documents/variation-report/aprovel-h-c-141-ii-0148-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Aprovel

Adopted

Reference Number: EMA/CHMP/388259/2013

English (EN) (60.97 KB - PDF)

**First published:** 28/06/2013

**Last updated:** 28/06/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-aprovel_en.pdf)

Aprovel-H-C-141-P45-0019 : EPAR - Assessment Report

Adopted

English (EN) (257.44 KB - PDF)

**First published:** 13/05/2013

**Last updated:** 13/05/2013

[View](/en/documents/variation-report/aprovel-h-c-141-p45-0019-epar-assessment-report_en.pdf)

Aprovel : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (115.61 KB - PDF)

**First published:** 16/10/2006

**Last updated:** 16/10/2006

[View](/en/documents/steps-after-cutoff/aprovel-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

Aprovel-H-C-141-II-0075 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (387.44 KB - PDF)

**First published:** 16/10/2006

**Last updated:** 16/10/2006

[View](/en/documents/scientific-discussion-variation/aprovel-h-c-141-ii-0075-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Aprovel : EPAR - Procedural steps taken before authorisation

English (EN) (95.95 KB - PDF)

**First published:** 16/10/2006

**Last updated:** 16/10/2006

[View](/en/documents/procedural-steps/aprovel-epar-procedural-steps-taken-authorisation_en.pdf)

Aprovel : EPAR - Scientific Discussion

English (EN) (492.74 KB - PDF)

**First published:** 16/10/2006

**Last updated:** 16/10/2006

[View](/en/documents/scientific-discussion/aprovel-epar-scientific-discussion_en.pdf)

#### News on Aprovel

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2013) 28/06/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

[European Medicines Agency recommendation on use of angiotensin-II-receptor antagonists during pregnancy](/en/news/european-medicines-agency-recommendation-use-angiotensin-ii-receptor-antagonists-during-pregnancy) 24/04/2008

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Aprovel : EPAR - Product Information - tracked changes

English (EN) (713 KB - DOC)

**First published:** 19/01/2026

[View](/en/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_en.doc)

[Other languages (24)](#file-language-dropdown-2)

български (BG) (485.12 KB - DOCX)

**First published:**

19/01/2026

[View](/bg/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_bg.docx)

español (ES) (367.27 KB - DOCX)

**First published:**

19/01/2026

[View](/es/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_es.docx)

čeština (CS) (352.74 KB - DOCX)

**First published:**

19/01/2026

[View](/cs/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (397.75 KB - DOCX)

**First published:**

19/01/2026

[View](/da/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (366.65 KB - DOCX)

**First published:**

19/01/2026

[View](/de/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (328.54 KB - DOCX)

**First published:**

19/01/2026

[View](/et/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (463.03 KB - DOCX)

**First published:**

19/01/2026

[View](/el/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_el.docx)

français (FR) (328.47 KB - DOCX)

**First published:**

19/01/2026

[View](/fr/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (404.79 KB - DOCX)

**First published:**

19/01/2026

[View](/hr/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (340.66 KB - DOCX)

**First published:**

19/01/2026

[View](/is/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_is.docx)

italiano (IT) (328.02 KB - DOCX)

**First published:**

19/01/2026

[View](/it/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (335.16 KB - DOCX)

**First published:**

19/01/2026

[View](/lv/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (345.47 KB - DOCX)

**First published:**

19/01/2026

[View](/lt/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (421.49 KB - DOCX)

**First published:**

19/01/2026

[View](/hu/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (1.42 MB - DOC)

**First published:**

19/01/2026

[View](/mt/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_mt.doc)

Nederlands (NL) (351.94 KB - DOCX)

**First published:**

19/01/2026

[View](/nl/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (300.27 KB - DOCX)

**First published:**

19/01/2026

[View](/no/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_no.docx)

polski (PL) (350.11 KB - DOCX)

**First published:**

19/01/2026

[View](/pl/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_pl.docx)

português (PT) (291.94 KB - DOCX)

**First published:**

19/01/2026

[View](/pt/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_pt.docx)

română (RO) (386.93 KB - DOCX)

**First published:**

19/01/2026

[View](/ro/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (369.69 KB - DOCX)

**First published:**

19/01/2026

[View](/sk/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (346.09 KB - DOCX)

**First published:**

19/01/2026

[View](/sl/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (306.91 KB - DOCX)

**First published:**

19/01/2026

[View](/fi/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (324.58 KB - DOCX)

**First published:**

19/01/2026

[View](/sv/documents/product-information-tracked-changes/aprovel-epar-product-information-tracked-changes_sv.docx)

#### More information on Aprovel

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

#### More information on Aprovel

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)
- [Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - referral](/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 19/01/2026

## Share this page

[Back to top](#main-content)